F. Abdul Karim

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

Pratima Chowdary, Stefan Lethagen, Ute Friedrich et al. · Journal of Thrombosis and Haemostasis · 2015 · 220 citations · Full text

Pharmacy, Immunology, Pharmacokinetics +13

Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia <scp>A</scp>: safety, efficacy and pharmacokinetics

Roshni Kulkarni, F. Abdul Karim, S. Glamocanin et al. · Haemophilia · 2013 · 61 citations

Medicine, Hematology, Pediatrics +15

Once‐weekly prophylactic treatment vs. on‐demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B

Lynne M. Smith, Kazimierz Kuliczkowski, Joan Korth‐Bradley et al. · Haemophilia · 2016 · 52 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Nonacog beta pegol in previously treated children with hemophilia B: results from an international open‐label phase 3 trial

Manuel Carção, F. Abdul Karim, Hideji Hanabusa et al. · Journal of Thrombosis and Haemostasis · 2016 · 50 citations · Full text

Medicine, Hematology, Pediatrics +10

Safety, efficacy and pharmacokinetics of rVIII‐SingleChain in children with severe hemophilia A: results of a multicenter clinical trial

Oleksandra Stasyshyn, Claudia Djambas Khayat, Genadi Iosava et al. · Journal of Thrombosis and Haemostasis · 2017 · 37 citations · Full text

Medicine, Hematology, Pharmacokinetics +16